Crinetics Pharmaceuticals (CRNX) EBITDA Margin (2017 - 2026)
Crinetics Pharmaceuticals' quarterly EBITDA Margin came in at 1220.09% in Q1 2026, up 2529930.0% year-on-year from N/an in Q1 2025, and up 38.96% quarter-over-quarter from 1998.77% in Q4 2025.
Crinetics Pharmaceuticals has reported EBITDA Margin for 10 years, with the latest figure at 1220.09% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 2529930.0% year-over-year to 1220.09%; the trailing twelve-month figure through Mar 2026 stood at 2765.2% (up 4018217.0% YoY), and the FY2025 full-year result was 6034.5%, up 2268754.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 1220.09%, up from 1998.77% in the prior quarter.
- The five-year high for EBITDA Margin was 1163.75% in Q1 2022, with the low at 90572.03% in Q3 2025.
- Average EBITDA Margin over 5 years is 15049.55%, with a median of 9717.66% recorded in 2022.
- Year-over-year, EBITDA Margin plunged 1593236 bps in 2025 and soared 2529930 bps in 2026.
- Tracing CRNX's EBITDA Margin over 5 years: stood at 6193.51% in 2022, then sank by 164 bps to 16363.58% in 2023, then decreased by 14 bps to 18645.36% in 2024, then soared by 89 bps to 1998.77% in 2025, then jumped by 39 bps to 1220.09% in 2026.
- The last three EBITDA Margin figures came in at 1220.09% (Q1 2026), 1998.77% (Q4 2025), and 90572.03% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | -1,220.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,220.09% |
| Dec 31, 2025 | -1,998.77% |
| Sep 30, 2025 | -90,572.03% |
| Jun 30, 2025 | -11,252.96% |
| Mar 31, 2025 | -26,519.39% |
| Jun 30, 2024 | -18,645.36% |
| Mar 31, 2024 | -10,587.03% |
| Sep 30, 2023 | -16,363.58% |
| Jun 30, 2023 | -5,077.94% |
| Mar 31, 2023 | -1,663.98% |
| Dec 31, 2022 | -6,193.51% |
| Sep 30, 2022 | -9,457.64% |
| Jun 30, 2022 | -9,977.68% |
| Mar 31, 2022 | -1,163.75% |
| Dec 31, 2021 | -2,890.91% |
| Dec 31, 2020 | 30,507.04% |
| Mar 31, 2020 | -24,423.94% |
| Dec 31, 2019 | -4,547.98% |
| Sep 30, 2019 | -2,864.55% |
| Mar 31, 2019 | -2,433.79% |
| Dec 31, 2018 | -1,079.90% |
| Sep 30, 2018 | -1,384.67% |
| Jun 30, 2018 | -847.49% |
| Mar 31, 2018 | -1,236.20% |
| Dec 31, 2017 | -473.67% |
| Sep 30, 2017 | -370.94% |
| Jun 30, 2017 | -197.48% |